Acute skin toxicity associated with a 1-week schedule of whole breast radiotherapy compared with a standard 3-week regimen delivered in the UK FAST-Forward Trial.
View/ Open
Date
2016-07-15Author
Brunt, AM
Wheatley, D
Yarnold, J
Somaiah, N
Kelly, S
Harnett, A
Coles, C
Goodman, A
Bahl, A
Churn, M
Zotova, R
Sydenham, M
Griffin, CL
Morden, JP
Bliss, JM
FAST-Forward Trial Management Group,
Type
Journal Article
Metadata
Show full item recordAbstract
BACKGROUND AND PURPOSE: FAST-Forward is a phase 3 clinical trial testing a 1-week course of whole breast radiotherapy against the UK standard 3-week regimen after primary surgery for early breast cancer. Two acute skin toxicity substudies were undertaken to test the safety of the test schedules with respect to early skin reactions. MATERIAL AND METHODS: Patients were randomly allocated to 40Gy/15 fractions (F)/3-weeks, 27Gy/5F/1-week or 26Gy/5F/1-week. Acute breast skin reactions were graded using RTOG (first substudy) and CTCAE criteria v4.03 (second substudy) weekly during treatment and for 4weeks after treatment ended. Primary endpoint was the proportion of patients within each treatment group with grade ⩾3 toxicity (RTOG and CTCAE, respectively) at any time from the start of radiotherapy to 4weeks after completion. RESULTS: 190 and 162 patients were recruited. In the first substudy, evaluable patients with grade 3 RTOG toxicity were: 40Gy/15F 6/44 (13.6%); 27Gy/5F 5/51 (9.8%); 26Gy/5F 3/52 (5.8%). In the second substudy, evaluable patients with grade 3 CTCAE toxicity were: 40Gy/15F 0/43; 27Gy/5F 1/41 (2.4%); 26Gy/5F 0/53. CONCLUSIONS: Acute breast skin reactions with two 1-week schedules of whole breast radiotherapy under test in FAST-Forward were mild.
Collections
Subject
FAST-Forward Trial Management Group
Breast
Skin
Humans
Breast Neoplasms
Radiodermatitis
Radiation Injuries
Radiotherapy Dosage
Female
Research team
Clinical Trials & Statistics Unit
Translational Breast Radiobiology
Language
eng
Date accepted
2016-02-22
License start date
2016-07
Citation
Radiotherapy and oncology : journal of the European Society for Therapeutic Radiology and Oncology, 2016, 120 (1), pp. 114 - 118
Publisher
ELSEVIER IRELAND LTD